Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Sigma Planning Corp

Sigma Planning Corp reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,147 shares of the biopharmaceutical company's stock after selling 4,321 shares during the period. Sigma Planning Corp's holdings in Gilead Sciences were worth $4,386,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Catalyst Financial Partners LLC lifted its holdings in Gilead Sciences by 6.3% during the 1st quarter. Catalyst Financial Partners LLC now owns 4,009 shares of the biopharmaceutical company's stock worth $449,000 after buying an additional 238 shares during the last quarter. Cohen Capital Management Inc. purchased a new stake in Gilead Sciences during the 1st quarter worth about $234,000. Signaturefd LLC lifted its holdings in Gilead Sciences by 5.8% during the 1st quarter. Signaturefd LLC now owns 23,338 shares of the biopharmaceutical company's stock worth $2,615,000 after buying an additional 1,276 shares during the last quarter. Edgestream Partners L.P. lifted its holdings in Gilead Sciences by 99.0% during the 1st quarter. Edgestream Partners L.P. now owns 18,401 shares of the biopharmaceutical company's stock worth $2,062,000 after buying an additional 9,152 shares during the last quarter. Finally, Cutter & CO Brokerage Inc. increased its position in shares of Gilead Sciences by 44.3% during the first quarter. Cutter & CO Brokerage Inc. now owns 6,423 shares of the biopharmaceutical company's stock worth $720,000 after purchasing an additional 1,972 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the sale, the insider owned 120,168 shares of the company's stock, valued at $13,238,908.56. This represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the sale, the chief financial officer directly owned 165,110 shares of the company's stock, valued at $18,190,168.70. The trade was a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,000 shares of company stock worth $6,623,445 in the last three months. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Trading Down 2.7%

GILD traded down $3.03 during trading on Tuesday, hitting $109.06. The company's stock had a trading volume of 4,937,556 shares, compared to its average volume of 7,686,671. The firm's 50 day moving average price is $107.93 and its 200-day moving average price is $104.88. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The stock has a market cap of $135.66 billion, a PE ratio of 22.96, a PEG ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a twelve month low of $70.21 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the previous year, the business earned ($1.32) earnings per share. The firm's quarterly revenue was down .3% compared to the same quarter last year. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.90%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GILD. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Morgan Stanley boosted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Oppenheimer dropped their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Nine investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $111.38.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.